Company intelligence / Profile preview

AVROBIO, Inc.

Cambridge, Massachusetts, United Statestectonictx.com ↗

Ownership: Private
Employees: ~42
Development stage: Phase 1

Overview

AVROBIO has reported positive results in a Phase 1/2 clinical trial for AVR-RD-01 in the treatment of Fabry disease, demonstrating significant enzyme activity restoration.

Therapeutic areas: Rare Diseases
Modalities: Ex vivo lentiviral-based gene therapies
Industry: Biotech

Drug pipeline

1 asset

TX45

Phase 1

Indications: Group 2 Pulmonary Hypertension, Heart Failure with Preserved Ejection Fraction

Beyond the preview

Go deeper on AVROBIO, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AVROBIO, Inc..

Explore the full profile